Marianne Waldstrøm

Marianne Waldstrøm

Auto-generated profile, based on publicly available information

Marianne Waldstrøm

Department of Clinical Pathology, University Hospital of Southern Denmark, Vejle, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
KSKarina Dahl Steffensen
Karina Dahl Steffensen
MMMadsen Madsen
Madsen Madsen
RARikke Andersen
Rikke Andersen
MWMarianne Waldstrøm
Marianne Waldstrøm
PAParvin Adimi
Parvin Adimi
Anders JakobsenAnders Jakobsen
Anders Jakobsen

9 November 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
Robson CarvalhoRobson Carvalho
Robson Carvalho
LCLuisa Matos do Canto
Luisa Matos do Canto
CACecilie Abildgaard
Cecilie Abildgaard
MJMads Jørgensen
Mads Jørgensen
MTMonica Søgaard Tronhjem
Monica Søgaard Tronhjem
SRSilvia Rogatto
Silvia Rogatto
Background: Serous ovarian carcinoma is the most frequent histological subgroup of ovarian cancer and the leading cause of death among gynecologic tumors. The tumor microenvironment and cancer-associated fibroblasts (CAFs) have a critical role in the origin and progression of cancer. We comprehensively characterized the crosstalk between CAFs and ovarian cancer cells from malignant fluids to identify specific ligands and receptors mediating intercellular communications and disrupted pathways related to prognosis and therapy response. Methods: Malignant fluids of serous ovarian cancer, including tumor-derived organoids, CAFs-enriched (eCAFs), and malignant effusion cells (no cultured) paired with normal ovarian tissues, were explored by RNA-sequencing. These data were integrated with single-cell RNA-sequencing data of ascites from ovarian cancer patients. The most relevant ligand and receptor interactions were used to identify differentially expressed genes with prognostic values in ovarian cancer. Results: CAF ligands and epithelial cancer cell receptors were enriched for PI3K-AKT, focal adhesion, and epithelial-mesenchymal transition signaling pathways. Collagens, MIF, MDK, APP, and laminin were detected as the most significant signaling, and the top ligand-receptor interactions THBS2/THBS3 (CAFs)—CD47 (cancer cells), MDK (CAFs)—NCL/SDC2/SDC4 (cancer cells) as potential therapeutic targets. Interestingly, 34 genes encoding receptors and ligands of the PI3K pathway were associated with the outcome, response to treatment, and overall survival in ovarian cancer. Up-regulated genes from this list consistently predicted a worse overall survival (hazard ratio > 1.0 and log-rank P < 0.05) in two independent validation cohorts. Conclusions: This study describes critical signaling pathways, ligands, and receptors involved in the communication between CAFs and cancer cells that have prognostic and therapeutic significance in ovarian cancer.

1 July 2019 in Gynecologic Oncology
Verified
Journal Article
Open access
BABerit Andersen
Berit Andersen
BCBirgitte Schütt Christensen
Birgitte Schütt Christensen
JCJette Christensen
Jette Christensen
DEDorthe Ejersbo
Dorthe Ejersbo
HHHanne Nørgaard Heje
Hanne Nørgaard Heje
MWMarianne Waldstrøm
Marianne Waldstrøm
In countries like Denmark, cervical cancer incidence is at present relatively high in elderly women, while routine screening stops at age 65 years. On this background, all women aged 69 and above were invited to human papillomavirus (HPV)-screening in Denmark in 2017. Women were identified from the Central Population Register and personally invited by digital or ordinary mail to have a screening sample taken by their general practitioner. In four regions, samples were tested for high risk (HPV) with the cobas 4800® HPV-assay, and in the last region with the BD Onclarity® HPV-assay. Participation rate, prevalence of high risk HPV, and proportion of positive samples with HPV16, HPV18, and other high risk HPV-types were tabulated by 5-year age-groups. 455,612 women were invited, and 30.2% (95 confidence interval (CI) 30.0-30.3) participated. Average age of participants was 74.6 years. Overall, 4.3% (95% CI 4.1-4.4) of participants were HPV-positive, of whom 24% had HPV 16/18. HPV-prevalence decreased slightly from 4.5% in women aged 69-73 years to 3.1% in women aged 84-88 years, but was 5.2% in the very small group of participants aged 89+ years. Invitation to HPV-screening was well received by elderly women. The HPV-prevalence decreased slightly with increasing age. No rebound of HPV-prevalence after menopause was found when our data were combined with previously published Danish data from younger women. The presently relatively high cervical cancer incidence in elderly women was not reflected in the HPV-prevalence.

25 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CACecilie Abildgaard
Cecilie Abildgaard
LCLuisa Matos do Canto
Luisa Matos do Canto
CRClaudia Aparecida Rainho
Claudia Aparecida Rainho
FMFabio Albuquerque Marchi
Fabio Albuquerque Marchi
NCNaiade Calanca
Naiade Calanca
SRSilvia Rogatto
Silvia Rogatto
Genetic and epigenetic changes contribute to intratumor heterogeneity and chemotherapy resistance in several tumor types. LncRNAs have been implicated, directly or indirectly, in the epigenetic regulation of gene expression. We investigated lncRNAs that potentially mediate carboplatin-resistance of cell subpopulations, influencing the progression of ovarian cancer (OC). Four carboplatin-sensitive OC cell lines (IGROV1, OVCAR3, OVCAR4, and OVCAR5), their derivative resistant cells, and two inherently carboplatin-resistant cell lines (OVCAR8 and Ovc316) were subjected to RNA sequencing and global DNA methylation analysis. Integrative and cross-validation analyses were performed using external (The Cancer Genome Atlas, TCGA dataset, n = 111 OC samples) and internal datasets (n = 39 OC samples) to identify lncRNA candidates. A total of 4255 differentially expressed genes (DEGs) and 14529 differentially methylated CpG positions (DMPs) were identified comparing sensitive and resistant OC cell lines. The comparison of DEGs between OC cell lines and TCGA-OC dataset revealed 570 genes, including 50 lncRNAs, associated with carboplatin resistance. Eleven lncRNAs showed DMPs, including the SNHG12. Knockdown of SNHG12 in Ovc316 and OVCAR8 cells increased their sensitivity to carboplatin. The results suggest that the lncRNA SNHG12 contributes to carboplatin resistance in OC and is a potential therapeutic target. We demonstrated that SNHG12 is functionally related to epigenetic mechanisms.

30 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LFLouise Faaborg
Louise Faaborg
RARikke Andersen
Rikke Andersen
MWMarianne Waldstrøm
Marianne Waldstrøm
JHJon Røikjær Henriksen
Jon Røikjær Henriksen
PAParvin Adimi
Parvin Adimi
KSKarina Dahl Steffensen
Karina Dahl Steffensen
Methylated Homeobox A9 circulating tumor DNA (meth-HOXA9) has been suggested as a blood-based biomarker in epithelial ovarian cancer (EOC), although its prognostic significance remains unproven. The aim of the present study was to investigate the prognostic impact of meth-HOXA9 in patients with recurrent EOC. DNA was purified from 4 mL plasma and, following bilsulfite conversion, meth-HOXA9 was analyzed using a methylation-specific droplet digital PCR. Detection of meth-HOXA9 was reported as a percentage of total DNA and as a binary variable (detectable and undetectable). Meth-HOXA9 status and its dynamics during palliative treatment were correlated with overall survival (OS) as the primary endpoint. At baseline, meth-HOXA9 was detected in 65.9% (83/126) of the patients. The median OS was 8.9 and 17.9 months in patients with detectable and undetectable meth-HOXA9 at baseline (hazard ratio: 2.04, p = 0.002), which remained significant in the multivariate analysis. Median OS in patients with an increase in meth-HOXA9 after one treatment cycle was 5.3 months compared to 33 months in patients with undetectable meth-HOXA9 (p < 0.001). Meth-HOXA9 was significantly related to poor survival and may serve as a prognostic marker in patients with recurrent EOC. The longitudinal monitoring of meth-HOXA9 is clinically feasible with the perspective of aiding clinical decision making.

1 September 2012
Verified
Journal Article
Closed access
CMChristine Vestergaard Madsen
Christine Vestergaard Madsen
KSKarina Dahl Steffensen
Karina Dahl Steffensen
DODorte Aalund Olsen
Dorte Aalund Olsen
MWMarianne Waldstrøm
Marianne Waldstrøm
CSCharlotte Hasselholt Søgaard
Charlotte Hasselholt Søgaard
Anders JakobsenAnders Jakobsen
Anders Jakobsen